Nextrials, Inc., a leader in clinical research software and services, has launched a significant upgrade for its flagship electronic data capture and clinical trial management platform, Prism. In addition to its new, more intuitive user interface, Prism now offers expanded functionality and interoperability with electronic health records from multiple vendors.
Prism users will immediately see improvements to its start page, where researchers can now evaluate project data from multiple studies organized into modules that can be easily collapsed and expanded for review. The “at a glance” statistics roll-up bar gives users fast facts such as enrollment status and data quality metrics. And with Prism’s newly streamlined structure, pop-up windows have been reduced in favor of intuitive layers within the browser, creating a more efficient work environment.
A significant change to Prism is its interoperability with data platforms more traditionally found within the healthcare environment for creating and managing electronic medical records. This gives life science companies many more options for implementing studies using patients and sites that were previously unavailable. Major incentives included in the American Recovery and Reinvestment Act (ARRA) will further promote the adoption of electronic medical records, increasing the number of potential sites that can benefit from Prism’s ability to mine data for clinical trials.
“Nextrials has been a leader in working with organizations such as CDISC and IHE to help facilitate the integration of data capture and management solutions used within clinical trials, such as Prism, with those used in hospitals, clinics and practitioner offices,” said James Rogers, co-founder and CEO of Nextrials. “The goal is to offer clinical trial sponsors access to a broader range of clinical investigators and potential patients. The streamlined data collection also provides efficiencies at the site and faster access to study data, helping sponsors hold the line on R&D costs while improving the drug development timeline.”
Nextrials expanded Prism’s report generation functionality earlier in the year to give users more powerful data mining capabilities. This ad hoc reporting feature has been further enhanced so that customers can now share reports with others, more easily monitor study progress and even drill down to analyze underlying data.
“Prism’s ad hoc reporting feature has been a very useful tool for our company,” said Debey Marti, senior director of clinical and regulatory data management & reporting at GlobeImmune Inc., a Colorado-based private company developing targeted molecular immunogens (Tarmogen products) for the treatment of cancer and infectious diseases. “Prism’s enhanced export capabilities are much more user-friendly, and allow us to review and monitor project data across multiple trials[kc1] .”
Prism 3.0 will continue to support mobile access to data via the Apple iPhone. This enables researchers to remotely view Prism’s new start page, reports and other tools for clinical trial data management in the same graphical formats seen on a desktop computer.
Nextrials expects Prism 3.0 to be in general availability before the end of the year. However, attendees at the 2009 Society for Clinical Data Management Annual Conference, being held at the Westin Seattle (WA) Hotel October 4-6, can get a first look at Nextrials’ Prism 3.0 in booth #301 and #303.
